Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Investor Presentation (April 2021)
36 slides from Nemaura Medical's investor presentation, Apr 7, 2021
Slide 1: Corporate Presentation April 2021
Corporate Presentation Nasdaq: NMRD April 2021
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified by use of terms such
Slide 3: It's Compelling… (user testimonial)
It’s Compelling… “I started using the sugarBEAT ® device, and after the first day I was in shock looking at the spikes in my sugar levels from the foods I was eating. I immediately took action and within 3 weeks I lost 11lbs just from adjusting my lifestyle and diet. sugarBEAT ® has allowed me to ke
Slide 4: Our Vision
Within 5 years, Nemaura aims to lead the wearables market and in the self - management of chronic diseases with our AI - driven pipeline of sensor products and our digital healthcare platforms . Our Vision Provide knowledge to empower users, using our BEAT® body - worn sensor platform. Glucose today
Slide 5: Company Overview
Company Overview □ Founded in 2011 , we developed a platform technology using non - invasive microsystems to measure blood markers at the surface of the skin. □ Developed and launched sugarBEAT ® Continuous Glucose Monitor, a CE approved Class 2b medical device with alarms and alerts for glucose mon
Slide 6: Where we are focusing first…
Where we are focusing first… There are over 463 million people living with diabetes worldwide, and over $ 760 Billion was spent in the US alone in 2019 for diabetes related healthcare expenditure 1 . The total addressable market exceeds $ 150 Billion 2 , 3 , 4 . Obesity and Diabetes are two of the m
Slide 7: The Pandemic of Chronic Conditions
The Pandemic of Chronic Conditions Adults in the U.S. have a chronic condition and 40% have more than one U.S. healthcare spend attributable to people with chronic and behavioral health conditions Annual total cost to the U.S. economy from chronic conditions 5 147M ~90% $3.7T
Slide 8: Preventing & Managing Type 2 Diabetes
Preventing & Managing Type 2 Diabetes Nemaura aims to stem the tide by preventing the onset of diabetes and helping to manage and/or reverse Type 2 diabetes using the world’s first body - worn sensor for non - invasive continuous glucose monitoring combined with world - class clinically validated di
Slide 9: Type 2 Diabetes: An American Health Crisis
TYPE 2 Diabetes: An American Health Crisis 6 One in three Americans has prediabetes. . . . . . and 90% of them don’t know it. $ $327 billion is spent on type 2 diabetes in the U.S., including direct medical costs and productivity loss. 327 billion
Slide 10: Our Unique Proposition
UNIQUE The world’s first daily wear CGM: no other sensor technology is currently available allowing non - invasive daily use. LIFESTYLE Other competing sensors are worn for 10 - 14 days consecutively. Nemaura’s BEAT® sensors are designed for daily use – any day you choose. Our Unique Proposition KNO
Slide 11: Total Addressable Market
Total Addressable Market UK 4.8 million people with diabetes 8 One person diagnosed every 2 minutes Germany 9.5 million have diabetes 9 . 4.5 million of these 9.5 million are undiagnosed and, as a result, may be particularly at risk. U.S. 34.2 million have diabetes 6 88 million people have pre - dia
Slide 12: Commercial Strategy: Geographic
Commercial Strategy: Geographic Digital solutions are not limited by geographical boundaries: post roll - out in the United States, we plan additional opportunities across allied geographic markets Europe Leverage similar compliance requirements and known healthcare structures to rapidly accelerate
Slide 13: Impact on Healthcare Cost
Impact on Healthcare Cost □ Healthcare costs for persons with type 2 diabetes cost approximately 2.5x as much as a person without diabetes. If they experience complications, that number soars even higher 10 □ Employers and healthcare insurers are therefor resorting to programs that will provide long
Slide 14: Product Portfolio
Product Portfolio Consumer Metabolic Health Program
Slide 15: CE approved Class IIB Medical Device
CE approved Class IIB Medical Device US FDA PMA approval and launch in the US anticipated by end of 2021 The world’s first daily wearable Continuous Glucose Monitor that doesn’t use needles. CE Approved Class IIb Medical Device
Slide 16: sugarBEAT
s ugarBEAT ® s ugarBEAT ®, a CE approved Class IIb Medical device, is the world’s first non - invasive CGM (Continuous Glucose Monitor) where the sensor sits on top of the skin. It does not require needles and does not puncture the skin to insert a sensor. We believe this to be a paradigm shift in t
Slide 17: sugarBEAT - How it Works
Discrete A small transmitter device and an adhesive patch with a sensor sits on top of the skin, typically on the upper arm Painless The system painlessly draws small amounts of glucose molecules out of the interstitial fluid just below the top layer of skin into a chamber within the patch. Does not
Slide 18: sugarBEAT and Time in Range
sugarBEAT ® and Time in Range A critical advantage of CGM - based systems is the ability to measure the time that glucose levels are in normal range – i . e . , time in range (TIR) . Control over TIR leads to a significant reduction in the onset of complications of diabetes . The same HbA 1 C values
Slide 19: sugarBEAT vs. HbA1C
sugarBEAT ® vs. HbA1C 40% high range 40% in range 20% low range 70% high range 25% in range 5% low range 100% in range The same HbA1C value, yet 3 completely different TIR profiles, demonstrating the power of TIR over HbA1C as the new gold standard 11
Slide 20: sugarBEAT - Intermittent Use
□ 10 - 14 day continuous monitoring is not essential for persons with Type 2, particularly those not on insulin □ High price points restrict access to those who benefit most □ Inconvenience of piercing skin with a sensor filament □ Inconvenience of keeping a device on one’s body for long periods of
Slide 21: sugarBEAT Testimonials
sugarBEAT ® Testimonials My Sugar Watch offered me a needle - free blood glucose monitoring solution that’s non - invasive and easy to use. I didn’t even realize I had the My Sugar watch device on my arm as it is so lightweight. It gives me the assurance that my blood sugar reading is accurate, and
Slide 22: sugarBEAT - Competitive Landscape
sugarBEAT ® - Competitive Landscape There are currently no other daily - use, skin - surface mounted (where sensor is not penetrating the skin) CGMs on the market. There are two key invasive sensor technologies on the market where the sensor is inserted inside the skin and remains there for 10 - 14
Slide 23: Type 2 Diabetes prevention and management program launched in the U.S.
Type 2 Diabetes prevention and management program launched in the U.S.
Slide 24: BEATdiabetes program
Combines glucose profiling using Nemaura’s CGM platform with a clinically validated digital program developed at the Joslin Diabetes Center 18 . It is a compelling program for the management and reversal of Type 2 diabetes World - class weight management & personalized lifestyle coaching to reverse
Slide 25: BEAT diabetes – How it Works
BEAT ® diabetes – How it Works proBEAT Ρ GLUCOSE PROFILING The world’s first daily - wear patch developed over a period of 10 years that discretely profiles a user’s blood sugar levels. No needles. No pain. A user wears the patch on any day they choose. Feedback report provides a picture of factors
Slide 26: BEAT diabetes - Expected Outcomes
BEAT ® diabetes - Expected Outcomes Digital behavior change at scale is leading the way in diabetes management with study outcomes exceeding traditional face - to - face clinical programs. Published literature demonstrates that over 60% of patients achieved diabetes reversal, and in over 75% of case
Slide 27: BEAT diabetes - Potential Outcome for Payers
BEAT ® diabetes - Potential Outcome for Payers Healthier Employees = Healthier Business $1,600 $4,700 $6,600 $9,100 Healthy (No conditions) Prediabetes only Hypertension Only Diabetes Only Annual Cost per Employee On average, diabetes costs both employers and insurers over $9,000 per year. Potential
Slide 28: BEAT diabetes - Competitor Programs
BEAT ® diabetes - Competitor Programs Livongo, recently acquired by Teledoc ($18B acquisition 20 ) Product/Service: A data - based health coaching program for persons with diabetes. Users share glucose results with certified diabetes educators and receive feedback in real time. Adoption: 164,000 use
Slide 29: BEAT Metabolic Health
BEAT Metabolic Health Metabolism is life.
Slide 30: Metabolic Health
Metabolic Health A mass - market consumer product A new program leveraging off the BEAT® wearable sensor platform to address improvements in metabolic health and well - being . Launching in 2021. Applicable to over 80 million people in the US with pre - diabetes as well as general health - conscious
Slide 31: 2021 Targets
Ramp up sales of sugarBEAT ® real time non - invasive continuous glucose monitor in UK and Key EU territories (with commercial marketing partners) 03 Launch sugarBEAT ® in the U.S. on PMA approval 04 Achieve Reimbursement in Germany and UK 05 Launch of consumer device and program addressing metaboli
Slide 32: Intellectual Property
Intellectual Property □ Nemaura is building an extensive and valuable intellectual property portfolio to position the company to become a global leader in the non - invasive wearable sensor market . □ Nemaura as over 30 patents across several patent families (both approved and pending), and substant
Slide 33: Future Product Opportunities: Lactate and Temperature Monitoring
CONTINUOUS LACTATE MONITORING Assists in threshold maximization in performance athletes Early identification of tissue hypoperfusion or shock for aggressive early resuscitation of critically ill patients to improve the their chances of survival BODY TEMPERATURE MONITORING Gives a more accurate and l
Slide 34: Future Product Opportunities: Alcohol and Drug Monitoring
ALCOHOL MONITORING Support personal health goals and provide warnings prior to driving. Provide physicians with individual’s drinking habits . Prevention of progression - to - alcohol - related disease DRUG MONITORING Monitoring the impact of drugs and personalized treatment plan for patients. Globa
Slide 35: Future Product Opportunities: Big Data and AI
BIG DATA Predictive analytics based on logic drawn from wearable medical devices using algorithms to seek patterns and structure in data and cluster them into groups or insights. Improving efficiencies per patient’s management of health care. Accuracy of diagnosis and treatment in personal medicine.
Slide 36: References
References 1. tps fai n/aboutdbeteswharis abetesfot gues hn 2. tp: frag devcom/slobarype2-dabetesmarket se tomas ble to587-illon 3, tps) tnewsuice com/news-leses/eoba-igta-dabetesmarte- uloekto 2026 16bikon nus opportunty 300980794. 4 tp abrosteraretsinsghscon/report/abst Nerina: Therapies or Dabete